For instance, recent studies have revealed that the tyrosine kinase inhibitor anlotinib can potentiate the efficacy of anti-PD-1 therapy by modulating the tumor microenvironment and enhancing CD8+T cell infiltration (Sha et al., 2024). This evidence concerns the gene CD8A and neoplasm.